J&J sued over oral cancer test kit; Valeant ups size of buyback plan to $1.8B;

@FiercePharma: Piramal sold off its generics biz to Abbott. Now, founder wants to grow overseas via $1.5B in deals. Item $ABT | Follow @FiercePharma

> A company that makes an oral cancer diagnostic kit is suing Johnson & Johnson ($JNJ) for $60 million, claiming that the healthcare giant blocked its test to protect Listerine. News

> Valeant Pharmaceuticals' ($VRX) board of directors has approved a $300 million increase in its share buyback plan, bringing the total authorized to $1.8 billion. Valeant release

> Paladin Labs ($PLB) continues to lobby shareholders of Afexa Life Sciences ($FXA) on its buyout offer, saying current management hasn't followed through on growth and R&D promises. Release

> Cheap drugs that could fight heart disease, such as aspirin and generic statin drugs, are not used often enough, particularly in the developing world. Story

> The U.S. Justice Department believed Google ($GOOG) CEO Larry Page knew about improper online pharmacy ads for years, but allowed them to continue, the Wall Street Journal said. Item

> A Canadian court authorized Labopharm to call a special shareholder meeting to approve its acquisition by Paladin Labs. Report

> Afexa Life Sciences ($FXA) said interim results from a trial of its Cold-FX flu remedy in children were encouraging. Article

Biotech News

@FierceBiotech: Study: Less than 1% of cancer patients enrolled in a clinical trial. Piece Very troubling. | Follow @FierceBiotech

@JohnCFierce: 52% of hospital/pharmacy purchasing agents bought drugs from gray market vendors in past 2 years. Price gouging? Article | Follow @JohnCFierce

@RyanMFierce: I have to think Medtronic folks are scrambling in the wake of the storm created by the insulin-pump hacker's report Story $MDT | Follow @RyanMFierce

@MaureenFierce: Pfizer (finally) wins a big one with crizotinib approval for lung cancer. News | Follow @MaureenFierce

> Adimab adds Novo, Biogen Idec to roster of antibody partners. More

> Zymeworks inks $187M Merck deal on bi-specific antibodies. Report

> Roche HDL drug dalcetrapib clears a crucial safety test. Item

> Pfizer, BMS unveil mega-blockbuster data on apixaban. Details

> Pfizer (finally) wins a big one with crizotinib approval for lung cancer. Story

> FDA demands more data on Novartis's ACZ885. News

> Actelion drug flunks PhII but safety data bolsters confidence in blockbuster PhIII. Article

Biotech IT News

> FierceBiotech IT's Labor Day schedule. News

> Alzheimer's trial database finds takers in W. Florida. More

> NexDocs opens the door to VC with $10.3M funding. Report

> Case Western spinoff wins NIH grant for software. News

> China a new frontier for growing clinical tech firm. Article

> Report: Samsung to test genetic analysis service. Details

> NIH pumping $25M to link EMR info to genetic data. Story

Medical Device News

> Lantos appoints CEO, closes Series B round. More

> Aleva raises $13.8M in Series A. Article

> Medtronic sees positive results with CoreValve. Report

> FDA clears Axis-Shield assay to diagnose RA. Story

> Abbott Molecular, Pfizer get nod for drug, companion Dx. Details

> Yates to head EMD Millipore. News

And Finally... Laughter helps cardiovascular health, but anger could literally cause a heart attack. Report

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.